Results 1 -
10
of
16
for
AXITINIB
- Axitinib is used alone to treat advanced renal cell carcinoma (RCC, a type of cancer that begins ... have not been treated successfully with another medication. Axitinib is used in combination with avelumab (Bavencio) or ...
- Targeted Therapy for Kidney Cancer (American Cancer Society)Kidney Cancer/Treatments and Therapies ... Kidney Cancer ... American Cancer Society ... Targeted drugs work differently on renal cell carcinoma (kidney cancer) than ...
- ... Avelumab injection is also used in combination with axitinib (Inlyta) as a first treatment for renal cell ...
- Targeted Therapy - Immunotherapy Combinations Effective for Advanced Kidney Cancer
(National Cancer Institute) ... kidney cancer, an immune checkpoint inhibitor combined with axitinib (Inlyta) was better than treatment with sunitinib (Sutent). - Renal cell cancer treatment options include surgery, radiation therapy, chemotherapy, biologic therapy, and targeted therapy. Learn more about the treatment ...
- Kidney Cancer/Diagnosis and Tests ... Kidney Cancer ... National Cancer Institute ... From the National Institutes of Health ... Renal cell cancer treatment options include ...
- Kidney Cancer/Start Here ... Kidney Cancer ... National Cancer Institute ... From the National Institutes of Health ... Renal cell cancer treatment options include surgery, ...
- Kidney Cancer/Treatments and Therapies ... Kidney Cancer ... This page lists cancer drugs approved by the Food and Drug Administration (FDA) for kidney cancer. The ...
- Kidney Cancer/Statistics and Research ... Kidney Cancer ... National Cancer Institute ... From the National Institutes of Health ... An overview and what's new of recent ...
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
(National Institute of Diabetes and Digestive and Kidney Diseases) (National Library of Medicine) LiverTox® provides regularly updated, unbiased and easily accessed information on the diagnosis, cause, frequency, clinical patterns and management of ...
